Delisting risk
Alaunos Therapeutics (TCRT)
Preclinical developer of ALN1003, an oral small molecule for obesity.
$1.69
At close+0.03 (+1.81%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | −1 | −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 6 | 7 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Research & development | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 0 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Other expenses | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −7 | −8 | −2 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 |
| −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other non-operating income | 1 | −5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −8 | −8 | −2 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 |
| Net income from continuing operations | −8 | −8 | −2 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 |
| Net income | −8 | −8 | −2 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 |
| EPS, basic | −$5.30 | −$4.90 | −$1.05 | −$0.71 | −$0.70 | −$0.46 | −$0.67 | −$0.63 | −$0.55 | −$0.40 | −$0.59 | −$0.41 |
| EPS, diluted | −$5.30 | −$4.90 | −$1.05 | −$0.71 | −$0.70 | −$0.46 | −$0.67 | −$0.63 | −$0.55 | −$0.40 | −$0.59 | −$0.41 |
| Weighted average shares, basic | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Weighted average shares, diluted | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| EBITDA | −7 | −3 | −2 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 |
| Depreciation & amortization | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −8 | −3 | −2 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 |